US-based clinical outsourcing specialist inVentiv Clinical Solutions has added three new members in Asia, Europe and Africa to the inVentiv Clinical Global Alliance, its network of clinical research partners in strategic locations around the world.

InVentiv kicked off the Alliance last October when it signed up ActivaCRO, a contract research organisation (CRO) with headquarters in Argentina and operations spanning Chile, Uruguay and Mexico. The rationale for the initiative is to leverage inVentiv Clinical’s services worldwide, delivering broader patient access and enhanced efficiencies for clients.

The new recruits are Protech Pharmaservices Corporation (PPC), Ecron Acunova and RDDA, which together with ActivaCRO will provide service coverage in more than 50 countries.

PPC, inVentiv Clinical’s partner for the Asia Pacific region, has headquarters in Taiwan and “vast clinical experience” across Asia, taking in Japan, China, Korea, Hong Kong, Singapore, Malaysia and Australia, the US company noted.

PPC offers a full spectrum of drug development solutions to the pharmaceutical, biotechnology, generic drug and medical device industries, including Phase I-IV clinical trial management, bioavailability/bioequivalence studies, central laboratory services, data management and statistical analysis.

Ecron Acunova, the Alliance partner for Europe, is the Bangalore-based CRO formed in late 2007 through Indian company Manipal Acunova’s acquisition of German CRO Ecron. The company has its European headquarters in Frankfurt, Germany and operations across Europe, Asia and the Americas.

It provides end-to-end services for Phase I-IV clinical research, including clinical trial management, clinical data management, pharmacokinetic/pharmacodynamic services and central laboratory capabilities for pharmaceutical, biotechnology, nutritional, medical diagnostic and medical device clients.

As inVentiv Clinical pointed out, Ecron Acunova has existing relationships with several members of the Global Alliance, including an ongoing collaboration with Essential CRO – acquired by inVentiv Clinical early this year – and a prior partnership with PPC in Taiwan.

The third new partner, RDDA, is a CRO based in Pretoria, South Africa. It offers regulatory, project management and monitoring support across Africa, spanning South Africa, Namibia, Botswana, Zambia, Kenya, Mozambique and Zimbabwe.

All qualifying members of the Global Alliance have to pass inVentiv Clinical’s quality reviews and agree to confidential terms around joint marketing plans, equity interests and other provisions designed to ensure a long-term, collaborative approach to global clinical trials.

inVentiv Clinical is a division of inVentiv Health, the US-based provider of clinical development, launch and commercialisation services to the pharmaceutical and healthcare industries that earlier this month agreed to be acquired by private equity firm Thomas H. Lee Partners for around US$1.1 billion.